1. Home
  2. APOG vs ABUS Comparison

APOG vs ABUS Comparison

Compare APOG & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

APOG

Apogee Enterprises Inc.

HOLD

Current Price

$40.83

Market Cap

835.9M

ML Signal

HOLD

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

HOLD

Current Price

$4.15

Market Cap

888.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
APOG
ABUS
Founded
1949
2005
Country
US
US
Employees
N/A
N/A
Industry
Auto Parts:O.E.M.
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
835.9M
888.5M
IPO Year
1994
2008

Fundamental Metrics

Financial Performance
Metric
APOG
ABUS
Price
$40.83
$4.15
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$47.00
$5.00
AVG Volume (30 Days)
203.6K
1.7M
Earning Date
04-09-2026
01-01-0001
Dividend Yield
2.64%
N/A
EPS Growth
N/A
13.64
EPS
1.74
N/A
Revenue
$1,360,994,000.00
$6,171,000.00
Revenue This Year
$4.12
$125.30
Revenue Next Year
N/A
N/A
P/E Ratio
$23.52
N/A
Revenue Growth
N/A
N/A
52 Week Low
$30.75
$2.71
52 Week High
$49.64
$5.10

Technical Indicators

Market Signals
Indicator
APOG
ABUS
Relative Strength Index (RSI) 58.25 48.15
Support Level $40.58 $3.93
Resistance Level $43.36 $4.34
Average True Range (ATR) 1.25 0.34
MACD 0.02 0.03
Stochastic Oscillator 61.93 57.27

Price Performance

Historical Comparison
APOG
ABUS

About APOG Apogee Enterprises Inc.

Apogee Enterprises Inc is a provider of architectural products and services for enclosing buildings, and high-performance glass and acrylic products used in applications for preservation, protection, and enhanced viewing. The company's operating segment consists of the Architectural Metals Segment, Architectural Services Segment, Architectural Glass Segment, and Performance Surfaces Segment. The company generates the majority of its revenue from the Architectural Metals Segment, which designs, engineers, fabricates, and finishes aluminum window, curtainwall, storefront, and entrance systems used principally in non-residential construction. The company generates revenue geographically from the United States, Canada, and Brazil, with the majority coming from the United States.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: